Chimeric antigen receptor T-cell therapy for relapsed mantle cell lymphoma: real-world experience from a single tertiary care center

Bone Marrow Transplant. 2022 Jun;57(6):1010-1012. doi: 10.1038/s41409-022-01658-x. Epub 2022 Apr 5.

Authors

Alexander D Heini¹, Ulrike Bacher², Marie-Noëlle Kronig¹, Gertrud Wiedemann², Urban Novak¹, Sacha Zeerleder², Behrouz Mansouri Taleghani², Michael Daskalakis², Thomas Pabst^{3

4}

Affiliations

¹ Department of Medical Oncology, Inselspital, Bern University Hospital, Bern, Switzerland.
² Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland.
³ Department of Medical Oncology, Inselspital, Bern University Hospital, Bern, Switzerland. thomas.pabst@insel.ch.
⁴ Department for Biomedical Research, University of Bern, Bern, Switzerland. thomas.pabst@insel.ch.

PMID: 35383289
DOI: 10.1038/s41409-022-01658-x

No abstract available

Publication types

Letter

MeSH terms

Adult
Cell- and Tissue-Based Therapy
Humans
Immunotherapy, Adoptive
Lymphoma, Mantle-Cell* / therapy
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen*
Tertiary Care Centers

Substances

Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen